TSE:GUD - Knight Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Knight Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add C$7.42 -0.01 (-0.13 %) (As of 02/21/2020 04:00 PM ET) Add Compare Today's RangeC$7.37Now: C$7.42▼C$7.4650-Day RangeC$7.42MA: C$7.76▼C$8.0852-Week RangeC$7.10Now: C$7.42▼C$8.88Volume127,484 shsAverage Volume238,147 shsMarket CapitalizationC$1.01 billionP/E Ratio49.14Dividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartEarningsInsider TradesHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Knight Therapeutics Inc operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Impavido, an alkyllysophospholipid analogue drug for visceral and cutaneous Leishmaniasis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; and Flat Tummy Tea, a herbal detox tea. Read More… Industry, Sector and Symbol Stock Exchange TSE Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolTSE:GUD Previous Symbol CUSIPN/A CIKN/A Webhttp://www.gud-knight.com/ Phone514-484-4483Debt Debt-to-Equity Ratio0.10 Current Ratio10.29 Quick Ratio10.03Price-To-Earnings Trailing P/E Ratio49.14 Forward P/E Ratio23.94 P/E Growth1055.5 Sales & Book Value Annual SalesC$14.08 million Price / Sales71.49 Cash FlowC$4.15 per share Price / Cash Flow1.79 Book ValueC$7.06 per share Price / Book1.05Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees27 Outstanding Shares135,629,000Market CapC$1.01 billion Next Earnings Date3/12/2020 (Estimated) OptionableNot Optionable Receive GUD News and Ratings via Email Sign-up to receive the latest news and ratings for GUD and its competitors with MarketBeat's FREE daily newsletter. TSX:GUD Rates by TradingView Knight Therapeutics (TSE:GUD) Frequently Asked Questions What is Knight Therapeutics' stock symbol? Knight Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "GUD." When is Knight Therapeutics' next earnings date? Knight Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Knight Therapeutics. What price target have analysts set for GUD? 4 Wall Street analysts have issued 12-month target prices for Knight Therapeutics' shares. Their forecasts range from C$8.50 to C$10.25. On average, they expect Knight Therapeutics' share price to reach C$9.58 in the next year. This suggests a possible upside of 29.2% from the stock's current price. View Analyst Price Targets for Knight Therapeutics. What is the consensus analysts' recommendation for Knight Therapeutics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Knight Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Knight Therapeutics. Has Knight Therapeutics been receiving favorable news coverage? Media stories about GUD stock have been trending negative recently, InfoTrie Sentiment reports. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Knight Therapeutics earned a news impact score of -2.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Knight Therapeutics. Who are some of Knight Therapeutics' key competitors? Some companies that are related to Knight Therapeutics include Evotec (EVT), Aurora Cannabis (ACB), Aphria (APHA), Ecofibre (EOF), HLS Therapeutics (HLS), OrganiGram (OGI), ORGANIGRAM-TS (OGI), Hexo (HEXO), HEXO (HEXO), Next Science (NXS), Benchmark (BMK), ICC Labs (ICC), Amryt Pharma (AMYT), Shield Therapeutics (STX) and Probiotec (PBP). What other stocks do shareholders of Knight Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Knight Therapeutics investors own include Constellation Software (CSU), Bombardier, Inc. Class B (BBD.B), Spin Master (TOY), Mondi (MNDI), Alimentation Couche-Tard (ATD.B), Brookfield Infrastructure Partners (BIP.UN), Canadian National Railway (CNR), Extendicare (EXE), Canopy Growth (WEED) and Aurora Cannabis (ACB). Who are Knight Therapeutics' key executives? Knight Therapeutics' management team includes the folowing people: Mr. Jonathan Ross Goodman BA, LLB, MBA, CEO & Director (Age 50)Ms. Samira Sakhia C.A., C.P.A., M.B.A., MBA, BCom, CPA, DPA, CA, Pres, CFO & Director (Age 50)Mr. Michel Loustric, Pres of Knight BarbadosMs. Amal Khouri, VP of Bus. Devel.Ms. Jody Engel, Director of Bus. Devel. How do I buy shares of Knight Therapeutics? Shares of GUD and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab. What is Knight Therapeutics' stock price today? One share of GUD stock can currently be purchased for approximately C$7.42. How big of a company is Knight Therapeutics? Knight Therapeutics has a market capitalization of C$1.01 billion and generates C$14.08 million in revenue each year. Knight Therapeutics employs 27 workers across the globe.View Additional Information About Knight Therapeutics. What is Knight Therapeutics' official website? The official website for Knight Therapeutics is http://www.gud-knight.com/. How can I contact Knight Therapeutics? The company can be reached via phone at 514-484-4483. MarketBeat Community Rating for Knight Therapeutics (TSE GUD)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 70 (Vote Outperform)Underperform Votes: 54 (Vote Underperform)Total Votes: 124MarketBeat's community ratings are surveys of what our community members think about Knight Therapeutics and other stocks. Vote "Outperform" if you believe GUD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GUD will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/22/2020 by MarketBeat.com StaffFeatured Article: Profit Margin
